slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 42,331-42,360
Pages 2,019
Rows per page 30
Component
42,331-42,360 of 60,568
26
The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
29
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
31
Includes FDA approval precedents in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
33
The slide uses a mix of expert quotes and a comparative table of clinical trials to validate the outpatient therapy thesis.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
41
The slide uses a scatter plot to map clinical trial outcomes (mPFS vs. prior lines of therapy) and a table to detail standard-of-care performance across lines of therapy.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
42
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a late-stage patient population.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
56
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
14
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
19
Includes commentary on EBIT margin dilution and CAPEX phasing.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
22
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
25
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
28
Includes a fashion photograph as a visual element.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
30
The waterfall chart shows the bridge from H1 2022 to H1 2023 revenue for Kering Eyewear.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
31
The table presents a standard income statement comparison between two half-year periods.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
32
The table highlights the impact of real estate acquisitions on free cash flow.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
38
EP&L stands for Environmental Profit & Loss. The slide uses a bubble matrix to show impact distribution and a line chart to show intensity reduction over time.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
46
Includes two donut charts representing store counts and revenue share, and a table detailing quarterly performance by geography.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
47
Includes two donut charts showing store count and revenue breakdown, plus a table of quarterly performance metrics.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
50
Kering | Investor Presentation Deck | 55 slidesKering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
51
The table shows a flat performance for the total group (0% change) despite varying performance across individual houses.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
52
The table is split into two sections: financial results and income tax metrics.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
53
Values in millions of Euros (€M).Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
03
Note at bottom: Lakeland's fiscal year end is January 31Lakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations Beat · Setup1 hit
05
Lakeland Bancorp | Results Presentation Deck | 14 slidesLakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations Beat · KPI Overview1 hit
09
Includes a footnote regarding the acquisition closing date.Lakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
The table shows growth across all key metrics including Net Sales, Gross Margin, Adjusted EBITDA, and EPS.Lakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations 1 hit
13
The table provides a transparent breakdown of non-GAAP adjustments including equity compensation, revaluation of earnout consideration, and facility start-up costs.Lakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations 1 hit
14
Lakeland Bancorp | Results Presentation Deck | 14 slidesLakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations 1 hit
12
The slide uses a table to establish clinical credibility for the MM-120 program by citing historical and contemporary research.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit